Pre-clinical assessment of chimeric antigen receptor t cell therapy targeting CD19+ B cell malignancy | Zendy

Sheng-I Hu | Zendy; Ming-Chin Ko | Zendy; Yi-Han Dai | Zendy; HsinAn Lin | Zendy; LihChyang Chen | Zendy; Shile Huang | Zendy; Te-Ling Pang | Zendy; ChengYi Kuo | Zendy; HsinChung Lin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pre-clinical assessment of chimeric antigen receptor t cell therapy targeting CD19+ B cell malignancy

Author(s) -

Sheng-I Hu,

Ming-Chin Ko,

Yi-Han Dai,

HsinAn Lin,

LihChyang Chen,

Shile Huang,

Te-Ling Pang,

ChengYi Kuo,

HsinChung Lin

Publication year - 2020

Publication title -

annals of translational medicine

Language(s) - English

Resource type - Journals

eISSN - 2305-5847

pISSN - 2305-5839

DOI - 10.21037/atm.2020.02.148

Subject(s) - cd19 , chimeric antigen receptor , flow cytometry , in vivo , in vitro , cell therapy , antigen , cancer research , cytotoxicity , immunology , microbiology and biotechnology , chemistry , cell , biology , t cell , immune system , biochemistry

UWC19 treatment effectively eliminated CD19 positive tumor cells with favorable toxicity profile. The findings suggest encouraging clinical prospects for its use in patients with CD19 positive B cell malignancies. Our study presented an alternative evaluation strategy for CAR-T cell products.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research